Landogrozumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Landogrozumab
Accession Number
DB11862
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
LY2495655
Categories
UNII
B1792M902R
CAS number
1391726-30-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Landogrozumab.
AbituzumabThe risk or severity of adverse effects can be increased when Landogrozumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Landogrozumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Landogrozumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Landogrozumab.
AducanumabThe risk or severity of adverse effects can be increased when Landogrozumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Landogrozumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Landogrozumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Landogrozumab.
AmatuximabThe risk or severity of adverse effects can be increased when Landogrozumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911252
Wikipedia
Landogrozumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMuscle Weakness1
2CompletedTreatmentMuscular Atrophy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:55 / Updated on June 04, 2019 07:28